Reusing Evidence from Eight Reference Jurisdictions for Hong Kong, China Listing

1. Key takeaways

Hong Kong, China does not conclude mutual recognition agreements with other markets. Its approach is one-way acceptance: it recognises marketing approvals issued by 8 reference jurisdictions as evidence in support of a listing application — the Chinese mainland, the United States, the European Union (member states that have implemented the European Council directives or regulations), Canada, Japan, Singapore, Korea and Australia. Evidence from these sources is reusable to different degrees: technical documentation can be reused to a high proportion, approval documents can be used directly, and labelling and vigilance documents require localisation.

• The relationship is one-way. An approval in a reference jurisdiction supports a Hong Kong, China listing; a Hong Kong, China listing does not support an approval elsewhere.
• Reuse is a matter of degree and document type, not a single yes or no answer for the whole file.
• An approval document carries conditions: the jurisdiction, the model covered, the risk class and the independence of the approval all have to line up.
• Labelling is the least reusable element and the one most often underestimated, because it looks like a translation task when it is a compliance task.
• Hong Kong, China classification must be determined independently. An overseas classification is supporting evidence, not a conclusion.

2. Legal basis

The acceptance route is set out in the notes to the expedited approval programme, the two listing guidelines and the published overview of the listing process, with labelling governed by the technical reference. Regulatory information was verified as of 29 October 2026; if an official document has since been updated, the latest published version prevails.

The legal basis separates two questions that are often merged in practice. The first is whether a document is accepted at all, which is answered by the list of recognised jurisdictions and the definition of an independent approval. The second is whether the content of the document satisfies the local requirement, which is answered by the guidelines and the technical reference. A file can pass the first test and fail the second, which is why an approval certificate alone is never a complete submission.

3. Expert insights

Insight one: technical documentation is the most reusable element. The evidence of safety, performance, risk management, verification and validation required in Hong Kong, China is closely related in structure to the technical documentation used in the Chinese mainland, the European Union and the United States. A technical file prepared for the EU MDR or the US FDA can, after structural mapping, directly support a Hong Kong, China listing (practical estimate). The mapping work is real but bounded: it is a matter of reorganising sections, not of generating new evidence, provided the original file is complete and current.

Insight two: the reuse of an approval document has preconditions. 4 conditions must be met at the same time: the approval must come from one of the 8 recognised jurisdictions, cover the model being applied for, carry an appropriate risk classification, and be independent rather than dependent on another approval. A European approval must identify the specific member state and the issuing body; a general reference to CE marking may attract a request for supplementary information. The independence condition is the one most often missed, because a certificate that derives its validity from a parent approval looks complete on its face.

Insight three: labelling and vigilance documents have the lowest reuse level. Hong Kong, China has the additional requirements of TR-005, and the Consumer Goods Safety Ordinance requires warnings directed at consumers to be expressed in Chinese and English, clearly and legibly. The Chinese must be traditional Chinese, with local terminology adjustments. This part must be redone; the Chinese mainland version cannot be carried over. Character conversion is not localisation: a warning that reads correctly in simplified Chinese may use a term that is not the one used by Hong Kong, China clinicians, and the requirement is about being understood by the user, not about being present on the label.

Insight four: two independent approvals can buy acceleration. A Chinese mainland approval plus an approval from any one other recognised jurisdiction satisfies the threshold of 2 or more independent regulatory approvals under the expedited approval programme. This is a structural advantage that manufacturers in the Chinese mainland hold over manufacturers with a single market. It is worth planning deliberately: the second approval is often available in a market the company already supplies, and the only missing step is to document it in the form the programme expects.

Insight five: mutual acceptance is not equivalence. Classification in Hong Kong, China must be determined independently under TR-003 or TR-006, and an overseas classification can only be used as corroboration. Carrying over an overseas classification directly is a common error. The error is costly because class determines the route, the documents and the assessment time; a file built on the wrong class has to be rebuilt rather than amended.

4. Practical recommendations

• Sort every document into three groups: reusable, to be verified, to be redone. Technical documentation is reusable, approval documents need verification, and labelling and vigilance documents need to be rebuilt.
• Secure two independent approvals first. Use the NMPA approval as the first and pursue a second from the United States, the European Union or Japan in order to enter the expedited approval programme.
• Determine the Hong Kong, China classification independently. Do not carry over an overseas classification, but file the overseas conclusion as corroboration.
• Localise the label at the design stage. Set the artwork for parallel Chinese and English content and traditional Chinese from the outset, rather than retrofitting it before submission.
• Keep the mapping record. Document how each reused section corresponds to the local requirement, so that a reviewer’s question can be answered by reference rather than by reconstruction.

5. Verification checklist

• □ All documents have been sorted under the three-group method
• □ Reference approval documents meet all 4 preconditions
• □ European approvals identify the specific member state and issuing body
• □ An independent Hong Kong, China classification determination has been completed
• □ Labels have been localised to TR-005 and the Chinese and English requirement
• □ Eligibility for the expedited approval programme (2 or more independent approvals) has been assessed
• □ The mapping record between reused sections and local requirements is on file

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support for Hong Kong, China. Our team manages adverse incident reporting and recall coordination with the Department of Health, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com